Ambeed.cn

首页 / / / / Mevastatin

美伐他汀 /Mevastatin {[allProObj[0].p_purity_real_show]}

货号:A445160 同义名: Compactin;ML236B

Mevastatin is the first discovered statin-class HMG-CoA reductase inhibitor used as a cholesterol-lowering agent isolated from Penicillium citinium.

Mevastatin 化学结构 CAS号:73573-88-3
Mevastatin 化学结构
CAS号:73573-88-3
Mevastatin 3D分子结构
CAS号:73573-88-3
Mevastatin 化学结构 CAS号:73573-88-3
Mevastatin 3D分子结构 CAS号:73573-88-3
规格 价格 会员价 库存 数量
{[ item.pr_size ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}

{[ getRatePrice(item.pr_rmb, 1,1) ]}

{[ getRatePrice(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_am, item.pr_size) ]}
{[ getRatePrice(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_am, item.pr_size) ]} {[ getRatePrice(item.pr_rmb_sale, 1,1) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate) ]} 现货 咨询 - +
购物车0 收藏 询单

Mevastatin 纯度/质量文件 产品仅供科研

货号:A445160 标准纯度: {[allProObj[0].p_purity_real_show]}
批次查询: 批次纯度:

全球学术期刊中引用的产品

Cell, 2024, 101755. Ambeed. [ A399663 ]
EMBO J., 2024. Ambeed. [ A295334 ]
JMC, 2024, 67(20): 18265-18289. Ambeed. [ A538667 , A341145 , A117430 , A172297 ]
JMC, 2024. Ambeed. [ A210558 , A1518164 ]
Cell Death Discov., 2024, 10, 436. Ambeed. [ A384235 ]
更多 >

Mevastatin 生物活性

描述 HMG-CoA reductase, the rate-limiting enzyme in the process of cholesterol synthesis in liver cells, catalyzes the production of mevalonate. Inhibiting HMG-CoA reductase inhibits cholesterol synthesis. Mevastatin reversibly inhibits HMG-CoA reductase and competes with HMG-CoA, whose Ki value is about 1 nM[3]. in vitro, at 0.01 pg/mL (26 nM), it reduced cholesterol synthesis by 50% compared with the control group[2]. In addition, mevastatin can completely inhibit L cell growth at 1.3 μM. Mevastatin can also influence cell cycle and change cell morphology in cultured fibroblasts[3]. In vivo, Mevastatin reduced serum cholesterol levels three hours after oral administration at doses of 5 mg/kg and 20 mg/kg. At a dose of 20 mg/kg, it reduces serum cholesterol levels by about 30 percent[2]. Mevastatin reduces cholesterol production in the liver by competitively inhibiting HMG-CoA reductase. Cholesterol levels were reduced only after 28 days of treatment and were not associated with a reduction in infarcts. After 14 days of high-dose treatment, baseline absolute cerebral blood flow was 30% higher[1]. In patients with familial hypercholesterolemia, mevastatin is effective in lowering plasma cholesterol. Treatment at 50 mg/day for 2 months reduced total cholesterol in FH heterozygous patients by 25%[3].

Mevastatin 动物研究

Dose Rabbit: 0.02 mg/kg[3] (intra-articular injections) Rat: 5 mg/kg, 20 mg/kg[2] (p.o.) Mice: 2 mg/kg, 20 mg/kg[1] (s.c.)
Administration Intra-articular injections, p.o., s.c.

Mevastatin 临床研究

NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点
NCT02441400 - Recruiting May 2019 Argentina ... 展开 >> Fundacion Favaloro Recruiting Buenos Aires, Argentina Contact: Alejandro Nieponice, MD          Principal Investigator: Alejandro Nieponice, MD          Austria University Hospital Vienna Recruiting Vienna, Austria Contact: Sebastian Schoppmann, MD          Principal Investigator: Sebastian Schoppmann, MD          Denmark Aarhus University Hospital Recruiting Aarhus, Denmark Contact: Jan B Pedersen, MD          Principal Investigator: Jan B Pedersen, MD          Germany SANA Klinikum Lichtenberg Recruiting Berlin, Germany Contact: Dirk Federlein          Principal Investigator: Dirk Hartmann, MD          Evangelisches Krankenhaus Castrop-Rauxel Recruiting Castrop Rauxel, Germany Contact: Pravin Thattamparambil, MD          Principal Investigator: Pravin Thattamparambil, MD          St. Marienstift Krankenhaus Friesoythe Recruiting Friesoythe, Germany Contact: Ralf Weise, MD          Principal Investigator: Ralf Weise, MD          Hospital zum Heiligen Geist Fritzlar Recruiting Fritzlar, Germany Contact: Carsten Bismarck          Principal Investigator: Carsten Bismarck, MD          Klinikum Garmisch-Partenkirchen Recruiting Garmisch-Partenkirchen, Germany Contact: Holger Vogelsang          Principal Investigator: Holger Vogelsang, MD          Asklepios Klinik Altona Recruiting Hamburg, Germany Contact: Gero Puhl          Principal Investigator: Gero Puhl          KRH Klinikum Siloah Hannover Oststadt Recruiting Hannover, Germany Contact: Ahmed Madisch          Principal Investigator: Ahmed Madisch, MD          Evangelisches Krankenhaus Herne Recruiting Herne, Germany Contact: Matthias Kemen, MD          Principal Investigator: Matthias Kemen, MD          Klinikum Konstanz Recruiting Konstanz, Germany Contact: Ulrike Petzsche          Principal Investigator: Marcus Schuchmann, MD          Heilig Geist-Krankenhaus Köln Recruiting Köln, Germany Contact: Ernst Eypasch, MD          Principal Investigator: Ernst Eypasch, MD          Universitätsklinikum Magdeburg Recruiting Magdeburg, Germany Contact: Frank Benedix          Principal Investigator: Ulrike von Arnim          Universitätsmedizin Mannheim Recruiting Mannheim, Germany Contact: Mirko Otto          Principal Investigator: Kai Nowak, MD          Klinikum Memmingen Recruiting Memmingen, Germany Contact: Heinz Schlosser          Principal Investigator: Carsten Gutt, MD          Friedrich-Ebert-Krankenhaus Neumünster Recruiting Neumünster, Germany Contact: Andrea Pace          Principal Investigator: Andrea Pace, MD          Asklepios Schwalm-Eder Kliniken GmbH Recruiting Schwalmstadt, Germany Contact: Norbert Hesselbarth          Principal Investigator: Felix Meuschke, MD          Jung Stilling - Siegen Recruiting Siegen, Germany Contact: Daniela-Patricia Borkenstein          Principal Investigator: Joachim Labenz, MD          St. Marien-Krankenhaus Siegen Recruiting Siegen, Germany Contact: Dietmar Stephan, MD          Principal Investigator: Dietmar Stephan, MD          Ev. Krankenhaus Wesel GmbH Recruiting Wesel, Germany Contact: Vivianda Menke          Principal Investigator: Vivianda Menke, MD          Mexico Hospital San José Recruiting Monterrey, Mexico Contact: David Aguirre Mar, MD          Principal Investigator: David Aguirre Mar, MD          Netherlands Maastricht University Medical Center Recruiting Maastricht, Netherlands Contact: Nicole Bouvy, MD          Principal Investigator: Nicole Bouvy, MD          United Kingdom Spire Leicester Hospital Recruiting Leicester, United Kingdom Contact: Chris Sutton          Principal Investigator: Chris Sutton, MD          University Hospital Southampton Recruiting Southampton, United Kingdom Contact: Abrie Botha          Principal Investigator: Abrie Botha, MD 收起 <<
NCT01382511 Pachyonychia Congenita Not Applicable Unknown - -

Mevastatin 参考文献

[3]The discovery and development of HMG-CoA reductase inhibitors

Mevastatin 实验方案

计算器
存储液制备 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.56mL

0.51mL

0.26mL

12.80mL

2.56mL

1.28mL

25.61mL

5.12mL

2.56mL

Mevastatin 技术信息

CAS号73573-88-3
分子式C23H34O5
分子量 390.513
别名 Compactin;ML236B;Mevastatin, Compactin.;Statin I;NSC 281245;L-637,312;CS 500
运输蓝冰
存储条件

液体 -20°C:3-6个月-80°C:12个月

粉末 Sealed in dry,2-8°C

溶解度

DMSO: 250 mg/mL(640.18 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO

动物实验配方
Ambeed 相关网站 Ambeed.cn Ambeed.com
Ambeed
关于我们
联系我们
资讯中心
网站地图
产品手册
  • 批次文件查询
  • 客户支持
    技术支持
    专业术语
    缩略词释义
    质量手册
    产品咨询
    计算器
    活动政策
    订购方法
    积分商城
    活动声明
    联系我们
    400-920-2911 sales@ambeed.cn tech@ambeed.cn
    Ambeed 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务,不为任何个人或者非科研性质用途提供服务。